Free Trial
NASDAQ:TRDA

Entrada Therapeutics (TRDA) Stock Price, News & Analysis

Entrada Therapeutics logo
$17.95 +0.02 (+0.11%)
(As of 11:01 AM ET)

About Entrada Therapeutics Stock (NASDAQ:TRDA)

Key Stats

Today's Range
$17.60
$18.01
50-Day Range
$13.65
$19.96
52-Week Range
$10.75
$20.49
Volume
21,899 shs
Average Volume
106,836 shs
Market Capitalization
$671.69 million
P/E Ratio
11.29
Dividend Yield
N/A
Price Target
$24.00
Consensus Rating
Buy

Company Overview

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Entrada Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
40th Percentile Overall Score

TRDA MarketRank™: 

Entrada Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 708th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Entrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Entrada Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Entrada Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Entrada Therapeutics are expected to decrease in the coming year, from $1.07 to ($3.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Entrada Therapeutics is 11.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.73.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Entrada Therapeutics is 11.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 91.28.

  • Price to Book Value per Share Ratio

    Entrada Therapeutics has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Entrada Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.68% of the float of Entrada Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Entrada Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Entrada Therapeutics has recently increased by 0.61%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Entrada Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Entrada Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.68% of the float of Entrada Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Entrada Therapeutics has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Entrada Therapeutics has recently increased by 0.61%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Entrada Therapeutics has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Entrada Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for TRDA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $410,816.00 in company stock.

  • Percentage Held by Insiders

    Only 7.59% of the stock of Entrada Therapeutics is held by insiders.

  • Percentage Held by Institutions

    86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Entrada Therapeutics' insider trading history.
Receive TRDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRDA Stock News Headlines

Download Our Tesla Ebook For Free
Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.
Oppenheimer Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
See More Headlines

TRDA Stock Analysis - Frequently Asked Questions

Entrada Therapeutics' stock was trading at $15.09 at the beginning of 2024. Since then, TRDA stock has increased by 19.0% and is now trading at $17.95.
View the best growth stocks for 2024 here
.

Entrada Therapeutics, Inc. (NASDAQ:TRDA) posted its quarterly earnings results on Tuesday, August, 13th. The company reported $1.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.90. The company earned $94.69 million during the quarter, compared to analyst estimates of $55 million. Entrada Therapeutics had a trailing twelve-month return on equity of 16.11% and a net margin of 25.53%.

Entrada Therapeutics (TRDA) raised $182 million in an initial public offering on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share.

Entrada Therapeutics' top institutional shareholders include FMR LLC (4.66%), Janus Henderson Group PLC (4.57%), Wellington Management Group LLP (2.75%) and Geode Capital Management LLC (1.54%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, Natarajan Sethuraman, Nathan J Dowden, Kory James Wentworth, Peter S Kim, Nerissa Kreher and John F Crowley.
View institutional ownership trends
.

Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
8/13/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/12/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRDA
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.00
High Stock Price Target
$28.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+33.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-6,680,000.00
Pretax Margin
35.51%

Debt

Sales & Book Value

Annual Sales
$129.01 million
Book Value
$11.29 per share

Miscellaneous

Free Float
34,580,000
Market Cap
$671.69 million
Optionable
Optionable
Beta
-0.26
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:TRDA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners